Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited (NASDAQ: PRE) generates an active stream of company news centered on its evolution as a health sciences business and the rapid growth of its IM8 premium health and longevity brand. Press releases describe Prenetics as a leading health sciences company focused on redefining the future of health and longevity through IM8, a premium core nutrition platform co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka.
News updates commonly highlight IM8’s growth milestones, including disclosures that the brand reached over $100 million in annualized recurring revenue within roughly 11 months of launch and has been characterized by the company as the fastest-growing supplement brand in industry history. Articles also cover monthly revenue achievements, subscription metrics, and international expansion, reflecting IM8’s role as the centerpiece of Prenetics’ strategy.
Investors following PRE can also expect news on capital allocation and financing activities. Recent announcements include a best efforts public offering of Class A ordinary shares with accompanying warrants, a voluntary warrant exchange program designed to reduce potential dilution and simplify the capital structure, and updates on the company’s Bitcoin treasury strategy. Prenetics has communicated a shift away from new Bitcoin purchases, choosing instead to maintain existing holdings as a treasury reserve while directing new capital exclusively toward IM8.
Another recurring theme in Prenetics news is strategic portfolio optimization. Releases describe the sale of ACT Genomics, the divestiture of Europa Sports Partners, and an ongoing review of other non-core assets such as CircleDNA and the company’s stake in Insighta. These items are presented as part of a broader effort to focus on IM8 and improve operating margins.
News items may also include earnings announcements, conference participation, and insider share purchases by members of the executive leadership team, which are furnished to the SEC on Form 6-K. For readers tracking PRE, this news page provides a consolidated view of operational updates, financial developments, capital structure changes, and strategic decisions affecting Prenetics and its IM8 brand.
Prenetics (NASDAQ: PRE) announced a multi-year global partnership making NBA champion Giannis Antetokounmpo a Global Partner and shareholder in IM8. IM8 reached $100M ARR in 11 months, delivered 22M servings, recorded 750,000 purchases across 31 countries, and expects $180–200M revenue in 2026. Prenetics reports ~$160M liquidity, zero debt, a $40M repurchase program, and adjusted EBITDA profitability targeted by Q4 2027. IM8 products are NSF Certified for Sport and supported by a 12-week randomized controlled trial.
Prenetics (NASDAQ: PRE) announced a strategic partnership between its IM8 brand and Superpower on March 24, 2026 to integrate clinical-grade supplementation with comprehensive blood diagnostics.
The deal offers IM8 90-day subscribers a $49 Superpower membership (75% off the $199 price), monthly subscribers a $99 rate, access to 100+ biomarker testing, Quest availability at >2,000 locations, and IM8 products featured in Superpower's personalized protocols.
Prenetics (NASDAQ: PRE) will attend the 38th Annual ROTH Conference in Laguna Niguel, CA, March 22–24, 2026. Management will hold one-on-one investor meetings and participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel at 12:00 p.m. PT on Monday, March 23, 2026. Both sessions will be available via webcast on the company’s investor relations website. To schedule meetings, investors should contact Investor Relations or their ROTH representative.
Prenetics (NASDAQ: PRE) authorized a $40.0 million share repurchase program over 12 months, bringing total insider and board-backed commitment to $42.75 million. The company reports $164 million in total adjusted liquidity, zero debt, and IM8 guidance of $180–200 million revenue for 2026, targeting adjusted EBITDA profitability by Q4 2027. Management purchased ~$2.75 million of stock in recent post-earnings windows. The program allows open market, negotiated and Rule 10b5-1 purchases and may be modified or suspended at any time.
Prenetics (NASDAQ: PRE) executives executed a second consecutive round of post-earnings open market purchases during Feb 23–27, 2026. The leadership team bought 76,060 shares for approximately $1.301 million at an average price of ~$17.11 per share.
Combined with prior purchases in November 2025, executives have personally invested about $2.75 million across two post-earnings windows. CEO Danny Yeung purchased 42,282 shares for ~$750,000 (~$17.71/share) in this round; other officers also made purchases. Management said the IM8 business is performing and the share price does not yet reflect that progress.
Prenetics (NASDAQ: PRE) launched IM8 Daily Ultimate Essentials PRO on February 23, 2026 — a clinical‑grade reformulation with up to 733% greater potency across 11 nutrients, new saffron nootropic, and bioactive vitamin upgrades.
The PRO formula adds two flavours (Mango + Passionfruit; Lemon + Orange), keeps the same price for new and existing customers, and auto‑upgrades subscribers at their next delivery. Product claims include >10,000 five‑star reviews, >670,000 purchases, and >20 million servings. Full supplement facts available at the product page.
Prenetics (NASDAQ: PRE) completed the sale of its 35% equity interest in Insighta to Tencent for $70.0 million, receiving $69.0 million on Feb 13, 2026 with $1.0 million in escrow.
As of Feb 15, 2026, total adjusted liquidity is $171.1 million (cash $99.3M; financial assets $29.3M; ACT escrow $6.3M; alternative assets $35.2M). The company reports zero outstanding debt and will report Q4 and full-year 2025 results pre-market on Feb 18, 2026.
Prenetics (NASDAQ: PRE) reported record FY2025 results: total revenue $92.4M (up ~480% YoY) and Q4 revenue of $36.6M (+55% QoQ). IM8 reached $10.0M monthly revenue in Dec 2025 and $120M ARR within 12 months, contributing $60.1M in FY2025.
Strategic divestitures (ACT Genomics, Europa, Insighta) boosted total adjusted liquidity to $171.1M as of Feb 15, 2026, with zero debt. Company reiterated 2026 IM8 revenue guidance of $180–$200M.
Prenetics (NASDAQ: PRE) appointed Dr. Darshan Shah to its Board of Directors, effective February 16, 2026. Dr. Shah joins the Audit, Compensation, and Nominating and Corporate Governance Committees and brings clinical longevity expertise, Mayo Clinic surgical training, and consumer product formulation experience highlighted by a Super Bowl Feb 6, 2026 appearance.
He founded Next Health, which plans >30 locations by end of 2026, and will support Prenetics’ IM8 clinical trials and product development efforts.
Prenetics (NASDAQ: PRE) completed the sale of its 35% equity interest in Insighta to Tencent for $70.0 million, receiving $69.0 million on Feb 13, 2026 with $1.0 million held in escrow.
As of Feb 15, 2026 total adjusted liquidity is $171.1 million (cash $99.3M; financial assets $29.3M; ACT escrow $6.3M; Bitcoin $35.2M). Prenetics reports zero outstanding debt and says proceeds will fund IM8 global expansion, innovation and clinical programs.